Tertatolol

Tertatolol

SCHEMBL49634

CC(C)(C)NCC(O)COc1cccc2c1SCCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 5/20 1.00
SLC6A4 P31645 3/20 1.00
ADRA2A P08913 3/20 1.00
SLC6A2 P23975 2/20 1.00
ADRB2 P07550 9/20 0.56
ADRB1 P08588 6/20 0.56
TSHR P16473 2/20 0.56
ADRA1A P35348 2/20 0.56
LMNA P02545 2/20 0.56
RECQL P46063 1/20 0.56
ADRB3 P13945 2/20 0.54
SIGMAR1 Q99720 1/20 0.54
CYP2D6 P10635 3/20 0.53
CYP1A2 P05177 2/20 0.53
USP2 O75604 1/20 0.53
CHRM1 P11229 1/20 0.53
CYP2C9 P11712 1/20 0.53
DRD1 P21728 1/20 0.53
TBXA2R P21731 1/20 0.53
PTGS1 P23219 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tertatolol SCHEMBL6513139 1.00 HTR1A (1.00) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
Tertatolol SCHEMBL49635 1.00 HTR1A (1.00) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
Tertatolol SCHEMBL23234262 0.99 HTR1A (0.98) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
Tertatolol SCHEMBL365413 0.99 HTR1A (0.98) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
Tertatolol SCHEMBL388069 0.99 HTR1A (0.98) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
Tertatolol SCHEMBL1649964 0.98 HTR1A (0.96) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
SCHEMBL9123669 0.85 HTR1A (0.74) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
Tertatolol SCHEMBL9136272 0.85 HTR1A (0.72) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
SCHEMBL9507435 0.82 SLC6A2 (0.70) HTR1ASLC6A4ADRA2ASLC6A2ADRB2
SCHEMBL11233727 0.81 ADRB2 (0.68) HTR1ASLC6A4ADRA2ASLC6A2ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4849 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
US-20250213647-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA 2025-07-03 US claimed
WO-2023212244-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS, INC. (US) 2023-11-02 WO claimed
WO-2023192319-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA (US) 2023-10-05 WO claimed
WO-2023183932-A2 MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) NEW YORK UNIVERSITY (US) 2023-09-28 WO claimed
US-20230279440-A1 METHODS TO GENETICALLY MODIFY CELLS FOR DELIVERY OF THERAPEUTIC PROTEINS CELLECTIS S.A. (FR) 2023-09-07 US claimed
EP-4146284-A1 METHODS TO GENETICALLY MODIFY CELLS FOR DELIVERY OF THERAPEUTIC PROTEINS Cellectis S.A. (FR) 2023-03-15 EP claimed
EP-3941570-A1 NEUROMODULATION CATHETER Ennovation, LLC (US) 2022-01-26 EP claimed
WO-2021224416-A1 METHODS TO GENETICALLY MODIFY CELLS FOR DELIVERY OF THERAPEUTIC PROTEINS CELLECTIS S.A. (FR) 2021-11-11 WO claimed
EP-3485908-B1 THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS MEREO BIOPHARMA 5 INC (US) 2021-08-18 EP claimed
EP-0312291-A2 Di-or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA MERCK & CO. INC. (US) 1989-04-19 EP claimed
EP-0312283-A2 Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA MERCK & CO. INC. (US) 1989-04-19 EP claimed
US-4782043-A HYPOTENSIVES MERCK & CO., INC. (US) 1988-11-01 US claimed
EP-0278158-A2 Renin inhibitors containing phenylalanyl-histidine replacements MERCK & CO. INC. (US) 1988-08-17 EP claimed
EP-0273696-A2 Renin inhibitors containing histidine replacements MERCK & CO. INC. (US) 1988-07-06 EP claimed
EP-0209897-A2 Peptide enzyme inhibitors MERCK & CO. INC. (US) 1987-01-28 EP claimed
EP-0157409-A2 Renin inhibitors containing 2-substituted statine MERCK & CO. INC. (US) 1985-10-09 EP claimed
EP-0156318-A2 C-terminal amide cyclic renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0156322-A2 Renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0129189-A2 Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same MERCK & CO. INC. (US) 1984-12-27 EP claimed